Prognostic role of hybrid PET/MRI in patient with Dasatinib-Induced Pulmonary Hypertension：A Case Report

Cancer drug therapies are associated with various cardiovascular complications, among which pulmonary hypertension (PH) has received increasing attention in recent years. Previous studies have demonstrated a link between 18 F-fluorodeoxyglucose (18 F-FDG) uptake and the progression of PH. We report the case of a 26-year-old female with a 33-month history of acute lymphoblastic leukemia (ALL) treated with dasatinib for 23 months. Ten months ago, the patient presented with symptoms of pulmonary hypertension and dasatinib was discontinued immediately. To further investigate the condition, the multimodal 18 F-FDG positron emission tomography / magnetic resonance (PET/MR) imaging was performed. It revealed manifestations consistent with PH from multiple morphological, functional and metabolic perspectives. The SUV RV / SUV LV and RVEF suggested a favorable prognosis. We can preliminarily infer that the pulmonary hypertension in this patient is related to dasatinib and is reversible, and the use of cardiac PET/MR imaging plays an indispensable role in early diagnosis and prognosis prediction.